Issues related to the frequency of exploratory analyses by evidence review groups in the NICE single technology appraisal process
Issues related to the frequency of exploratory analyses by evidence review groups in the NICE single technology appraisal process
Background Evidence Review Groups (ERGs) critically appraise company submissions as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process. As part of their critique of the evidence submitted by companies, the ERGs undertake exploratory analyses to explore uncertainties in the company’s model. The aim of this study was to explore pre-defined factors that might influence or predict the extent of ERG exploratory analyses. Objective The aim of this study was to explore predefined factors that might influence or predict the extent of ERG exploratory analyses. Methods We undertook content analysis of over 400 documents, including ERG reports and related documentation for the 100 most recent STAs (2009–2014) for which guidance has been published. Relevant data were extracted from the documents and narrative synthesis was used to summarise the extracted data. All data were extracted and checked by two researchers. Results Forty different companies submitted documents as part of the NICE STA process. The most common disease area covered by the STAs was cancer (44%), and most ERG reports (n = 93) contained at least one exploratory analysis. The incidence and frequency of ERG exploratory analyses does not appear to be related to any developments in the appraisal process, the disease area covered by the STA, or the company’s base-case incremental cost-effectiveness ratio (ICER). However, there does appear to be a pattern in the mean number of analyses conducted by particular ERGs, but the reasons for this are unclear and potentially complex. Conclusions No clear patterns were identified regarding the presence or frequency of exploratory analyses, apart from the mean number conducted by individual ERGs. More research is needed to understand this relationship.
99-108
Kalthenthaler, Eva
f470af41-b041-4ece-b9c0-56bcbedef375
Carroll, Christopher
73b828e7-ad05-42f3-8878-87c5168e8b9c
Hill-McManus, Daniel
1c4481a7-a4e0-489f-9420-0af0fc3395c3
Scope, Alison
ae59f074-f374-47fc-996e-a911373add8a
Holmes, Michael
0728404e-9cbc-4ddc-8224-0503ea919edc
Rice, Stephen
c161c01e-5d6b-4235-8438-48aeec70f4bf
Rose, Micah
f6deee44-f21f-4d14-90a9-f7a449d0adba
Tappenden, Paul
aa3fcbbb-cf8c-4c59-a7de-4ab870d689fe
Woolacott, Nerys
51a97637-05a7-49ec-9209-993ee8d6ae4c
June 2017
Kalthenthaler, Eva
f470af41-b041-4ece-b9c0-56bcbedef375
Carroll, Christopher
73b828e7-ad05-42f3-8878-87c5168e8b9c
Hill-McManus, Daniel
1c4481a7-a4e0-489f-9420-0af0fc3395c3
Scope, Alison
ae59f074-f374-47fc-996e-a911373add8a
Holmes, Michael
0728404e-9cbc-4ddc-8224-0503ea919edc
Rice, Stephen
c161c01e-5d6b-4235-8438-48aeec70f4bf
Rose, Micah
f6deee44-f21f-4d14-90a9-f7a449d0adba
Tappenden, Paul
aa3fcbbb-cf8c-4c59-a7de-4ab870d689fe
Woolacott, Nerys
51a97637-05a7-49ec-9209-993ee8d6ae4c
Kalthenthaler, Eva, Carroll, Christopher, Hill-McManus, Daniel, Scope, Alison, Holmes, Michael, Rice, Stephen, Rose, Micah, Tappenden, Paul and Woolacott, Nerys
(2017)
Issues related to the frequency of exploratory analyses by evidence review groups in the NICE single technology appraisal process.
PharmacoEconomics Open, 1 (2), .
(doi:10.1007/s41669-016-0001-4).
Abstract
Background Evidence Review Groups (ERGs) critically appraise company submissions as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process. As part of their critique of the evidence submitted by companies, the ERGs undertake exploratory analyses to explore uncertainties in the company’s model. The aim of this study was to explore pre-defined factors that might influence or predict the extent of ERG exploratory analyses. Objective The aim of this study was to explore predefined factors that might influence or predict the extent of ERG exploratory analyses. Methods We undertook content analysis of over 400 documents, including ERG reports and related documentation for the 100 most recent STAs (2009–2014) for which guidance has been published. Relevant data were extracted from the documents and narrative synthesis was used to summarise the extracted data. All data were extracted and checked by two researchers. Results Forty different companies submitted documents as part of the NICE STA process. The most common disease area covered by the STAs was cancer (44%), and most ERG reports (n = 93) contained at least one exploratory analysis. The incidence and frequency of ERG exploratory analyses does not appear to be related to any developments in the appraisal process, the disease area covered by the STA, or the company’s base-case incremental cost-effectiveness ratio (ICER). However, there does appear to be a pattern in the mean number of analyses conducted by particular ERGs, but the reasons for this are unclear and potentially complex. Conclusions No clear patterns were identified regarding the presence or frequency of exploratory analyses, apart from the mean number conducted by individual ERGs. More research is needed to understand this relationship.
Text
10.1007_s41669_016_0001_4.pdf
- Version of Record
More information
e-pub ahead of print date: 4 November 2016
Published date: June 2017
Identifiers
Local EPrints ID: 412821
URI: http://eprints.soton.ac.uk/id/eprint/412821
ISSN: 2509-4254
PURE UUID: 607ea072-569e-4b24-a3b5-151cea4f0598
Catalogue record
Date deposited: 02 Aug 2017 16:30
Last modified: 10 May 2024 16:56
Export record
Altmetrics
Contributors
Author:
Eva Kalthenthaler
Author:
Christopher Carroll
Author:
Daniel Hill-McManus
Author:
Alison Scope
Author:
Michael Holmes
Author:
Stephen Rice
Author:
Micah Rose
Author:
Paul Tappenden
Author:
Nerys Woolacott
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics